# EDGAR Filing Document

**Accession Number:** 0001842295
**File Stem:** 0001140361-26-017475
**Filing Date:** 2026-4
**Character Count:** 1199
**Document Hash:** c6c25cc9a258072770650b282f7c3c91
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-017475.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001140361-26-017475

**CONFORMED SUBMISSION TYPE**: ARS

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**EFFECTIVENESS DATE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Maze Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001842295
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** ARS
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42490
- **FILM NUMBER:** 26908469

**BUSINESS ADDRESS:**
- **STREET 1:** 171 OYSTER POINT BOULEVARD, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 6508505070

**MAIL ADDRESS:**
- **STREET 1:** 171 OYSTER POINT BOULEVARD, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### Attached PDF Documents

**Attachment 1:** `ef20071733_ars.pdf`

_No text found in this document._